About NAD(P)H oxidoreductase RTN4IP1, mitochondrial
NAD(P)H oxidoreductase RTN4IP1, mitochondrial (RTN4IP1) is a protein
from Homo sapiens identified by UniProt accession
Q8WWV3, 396 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | NAD(P)H oxidoreductase RTN4IP1, mitochondrial |
| UniProt accession | Q8WWV3 |
| Gene | RTN4IP1 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (65)
Diseases linked to this target (Open Targets).
- Autosomal recessive isolated optic atrophy · score 0.63
- neurodegenerative disease · score 0.52
- genetic disorder · score 0.34
- gut microbiome measurement · score 0.24
- blood protein measurement · score 0.21
- urate measurement · score 0.20
- creatinine measurement · score 0.18
- DNA methylation · score 0.17
- blood urea nitrogen measurement · score 0.17
- Global developmental delay · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WWV3-F1 | alphafold | PREDICTED | 91.77 | — |
Amino-acid sequence (396 residues)
MEFLKTCVLR RNACTAVCFW RSKVVQKPSV RRISTTSPRS TVMPAWVIDK YGKNEVLRFT QNMMMPIIHY PNEVIVKVHA ASVNPIDVNM RSGYGATALN MKRDPLHVKI KGEEFPLTLG RDVSGVVMEC GLDVKYFKPG DEVWAAVPPW KQGTLSEFVV VSGNEVSHKP KSLTHTQAAS LPYVALTAWS AINKVGGLND KNCTGKRVLI LGASGGVGTF AIQVMKAWDA HVTAVCSQDA SELVRKLGAD DVIDYKSGSV EEQLKSLKPF DFILDNVGGS TETWAPDFLK KWSGATYVTL VTPFLLNMDR LGIADGMLQT GVTVGSKALK HFWKGVHYRW AFFMASGPCL DDIAELVDAG KIRPVIEQTF PFSKVPEAFL KVERGHARGK TVINVV
Explore NAD(P)H oxidoreductase RTN4IP1, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets